Shivaani Kummar, M.D.
National Cancer Institute (NCI)
9
9
9
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (9)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
E-mail: ClinicalTrials@ ImClone.com
Eli Lilly and Company
Shared therapeutic areas:
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Zhaohui Zhu, MD
Peking Union Medical College Hospital
Shared therapeutic areas:
Tim F Greten, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Puma
Biotechnology
Shared therapeutic areas:
Norman Wolmark, MD
NSABP Foundation Inc
Shared therapeutic areas:
Worked with same sponsors:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (9)
Showing 9 of 9 trials
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Safety of Batracylin in Patients With Solid Tumors and Lymphomas
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases
An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas
EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer
All 9 trials loaded